Intersect Ent Inc
NASDAQ:XENT
Intrinsic Value
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of XENT.
Intersect Ent Inc's market capitalization is 954.8m USD.
XENT stock price is 28.24 USD.
XENT.
XENT. Open DCF Valuation
XENT. Open Relative Valuation
XENT.
XENT's ROIC (Return on Invested Capital) has decreased in the last 3 years from -76% to -78%, and is approaching profitability.
XENT's Revenue has grown by an exceptional 22% over the past 12 months.
XENT's ROE (Return on Equity) has significantly increased in the last 3 years from -93% to 807%.
XENT's short-term assets (87m USD) exceed its short-term liabilties (46m USD).
XENT has positive Net Debt. This means that the company has more debt (143m USD) than cash and short-term investments (51m USD).
XENT has negative Operating Income for the last twelve months.
XENT has negative Net Income for the last twelve months.
XENT's ROE (Return on Equity) for the past 12 months is very high and is equal to 807%.
XENT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -78%.
XENT's long-term liabilties (221m USD) exceed its long-term assets (127m USD).
XENT has positive Gross Profit for the last twelve months.
XENT has negative Free Cash Flow for the last twelve months.
XENT has very high three-year average ROE (Return on Equity): 1 191%. The company is very efficient at transforming stockholders' equity into net income.
XENT has negative three-year average ROIC (Return on Invested Capital): -103%. The company is not efficient at using invested capital to generate operating income.
XENT's D/E (Debt to Equity) is very low and is equal to -1.52.
XENT's Altman Z-Score is very low and is equal to -4.13.
XENT doesn't generate enough operating income (-78m USD) to safely cover interest payments on its debt (3m USD).
Fundamental Analysis
Intersect Ent Inc
Balance Sheet Decomposition
Intersect Ent Inc
| Current Assets | 87.5m |
| Cash & Short-Term Investments | 50.6m |
| Receivables | 13.2m |
| Other Current Assets | 23.6m |
| Non-Current Assets | 39.9m |
| PP&E | 20.3m |
| Other Non-Current Assets | 19.6m |
| Current Liabilities | 46.4m |
| Accounts Payable | 9.2m |
| Accrued Liabilities | 14.7m |
| Other Current Liabilities | 22.5m |
| Non-Current Liabilities | 175m |
| Long-Term Debt | 142.6m |
| Other Non-Current Liabilities | 32.4m |
Earnings Waterfall
Intersect Ent Inc
|
Revenue
|
104m
USD
|
|
Cost of Revenue
|
-29.3m
USD
|
|
Gross Profit
|
74.7m
USD
|
|
Operating Expenses
|
-152.8m
USD
|
|
Operating Income
|
-78m
USD
|
|
Other Expenses
|
-90.4m
USD
|
|
Net Income
|
-168.4m
USD
|
Free Cash Flow Analysis
Intersect Ent Inc
What is Free Cash Flow?
XENT Profitability Score
Profitability Due Diligence
Intersect Ent Inc's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Score
Intersect Ent Inc's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
XENT Solvency Score
Solvency Due Diligence
Intersect Ent Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Intersect Ent Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XENT Price Targets Summary
Intersect Ent Inc
Ownership
XENT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
XENT Price
Intersect Ent Inc
| Average Annual Return | -11.29% |
| Standard Deviation of Annual Returns | 7.05% |
| Max Drawdown | -73% |
| Market Capitalization | 954.8m USD |
| Shares Outstanding | 33 813 700 |
| Percentage of Shares Shorted | 9.59% |
Company Profile
Intersect Ent Inc
Country
Industry
Market Cap
Dividend Yield
Description
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company is headquartered in Menlo Park, California and currently employs 433 full-time employees. The company went IPO on 2014-07-24. The firm's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company also offers ENT products, such as VenSure and CUBE.
You don't have any saved screeners yet
